Insights
Insights on health, access and innovation
Read practical thinking from Newmarket Strategy on the policy, access, reimbursement and health system issues shaping healthcare and life sciences.
Early Value Assessment; NICE’s new push for digital, diagnostics and devices
As absolutely no one has failed to notice, the coronavirus pandemic has injected new energy into the digital transformation agenda. Incoming NHS Transformation Director Tim Ferris has continued to focus on…
DHSC: Plan for Digital Health and Social Care
On 29th June, A plan for digital health and social care was released by the Department of Health and Social Care. The goal of the plan is to create a digital…
10 lessons for partners to the NHS elective recovery programme
At Newmarket Strategy, we work with a range of NHS organisations, partners, and suppliers on the elective recovery challenge. As the NHS approaches its first delivery milestone (eradicating >104wk waits)…
Patient and public involvement and engagement needs to happen at all levels of healthcare decision making
Patient and public involvement and engagement means that “activities and research are carried out ‘with’ or ‘by’ members of the public or patients, rather than ‘to’, ‘about’ or ‘for’ them”[1].…
Severity modifier – to discount or not to discount?
One of the wins to come out of the recent NICE methods review, according to Industry and others in the Life Sciences ecosystem, was the introduction of the severity modifier.[i] The…
The Innovative Medicines Fund: Regressive Measures or A Worthy Successor?
A new Innovative Medicines Fund (IMF), the NHS England consultation on which closed last Friday, has the potential to make a meaningful impact on patient access to innovative, new medicines in England for…
Events
